Galectin-3 in heart recipients
https://doi.org/10.15825/1995-1191-2019-2-145-149
Abstract
This review summarizes the current literature devoted to the analysis of the diagnostic and prognostic role of biomarker galectin-3 in patients with heart failure and heart recipients. Measuring the level of galectin-3 in heart recipients may presumably be important for assessing the risk of developing rejection and fibrosis of the transplanted heart, but data on the effectiveness of galectin-3 as a biomarker for the development of post-transplant complications are not enough, further studies are needed.
About the Authors
A. A. Ulybysheva
V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation; N.I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Ulybysheva Adelya Anverovna
1, Shchukinskaya str., Moscow, 123182, Tel. (499) 190-38-77
O. P. Shevchenko
V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University)
Russian Federation
Russian Federation
O. E. Gichkun
V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University)
Russian Federation
Russian Federation
A. О. Shevchenko
V.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation; N.I. Pirogov Russian National Research Medical University; I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University)
Russian Federation
Russian Federation
References
1. Patel JK, Kobashigawa JA. Thoracic organ transplantation: Laboratory methods. Methods in Molecular Biology. 2013; 1034: 127-143.
2. Labarrere CA, Jaeger BR. Biomarkers of heart transplant rejection: the good, the bad, and the ugly! Trans-plantionalResearch. 2012; 159 (4): 238-251.
3. Shevchenko AO, Nasyrova AA, Tunyaeva IU, Ilynsky IV, Shevchenko OP, Poptzov VN, Gautier SV Cardiac transplant rejection correlated with non-invasive predictors: common carotid artery wall functional indices and blood levels of biomarkers. ESOT Brussels. 2015; 53 (S1): 367.
4. MaiselAS. Cardiac biomarkers: expert advice for clinicians. JayPee Brothers. 2012.
5. McMinn JF, Lang NN, McPhadden A et al. Biomarkers of acute rejection following cardiac transplantation. Biomarkers in Medicine. 2014; 8 (6): 815-832.
6. Velikiy DA, Gichkun OE, Shevchenko AO. Mikro-RNK: rol' v razvitii serdechno-sosudistykh zabolevanij, perspektivy' klinicheskogo primeneniya. Klinicheskaya laboratornaya diagnostika. 2018; 63 (7): 403-409. [In Russ, English abstract].
7. Savic-Radojevic A, Pljesa-Ercegovac M, Matic M et al. Novel biomarkers of heart failure. Advansed in Clinical Chemistry. 2016. DOI: 10.1016/bs.acc.2016.09.002
8. Diaz-Alvarez L, Ortega E. The Many Roles of Galec-tin-3, a Multifaceted Molecule, in Innate Immune Responses against Pathogens. Mediators Inflamm. 2017. doi: 10.1155/2017/9247574.
9. Dalzell JR, Jackson CE, McDonagh TA, Gardner RS. Novel biomarkers in heart failure: An overview. Biomarkers in Medicine. 2009; 3 (5): 453-463.
10. Vasiljeva OA, Yakushina VD, Ryazantseva NV, Novitsky VV Use galectine-3 in laboratory diagnostics. Kliniko-laboratornyy konsilium. 2011; 2: 12-16. [In Russ, English abstract].
11. Sharma UC, Pokharel S, van Brakel TJ et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004; 110: 3121-3128.
12. Hoyer KK, Pang M, Gui D et al. An antiapoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol. 2004; 164: 893-902.
13. Bik MA. The role of galektin-3 and galektin-9 in the chronic inflammation of rheumatoid arthritis. A thesis submitted to the University of Birmingham for the degree of Doctor of Philosophy. 2009: 1-194.
14. van Kimmenade RR, Januzzi JLJr, Ellinor PT et al. Utility of amino-terminal probrain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006; 48: 1217-1224.
15. Felker GM, FiuzatM, Shaw LK et al. Prognostic value of galectin-3 in chronic heart failure: results from the HF-ACTION study. Eur Heart J. 2010; 31 (Suppl 1): 429.
16. Medvedeva EA, Berezin II, Surkova EA, Yaranov DM, Shchukin YV. Galectin-3 in patients with chronic heart failure: association with oxidative stress, inflammation, renal dysfunction and prognosis. Minerva Cardioangiol. 2016; 64 (6): 595-602.
17. De Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010; 7 (1): 1-8.
18. Lok DJA, van der Meer P, Bruggink-Andre' de la Porte PW et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. ClinResCardiol. 2010; 99: 323-328.
19. Meijers WC, van der Velde AR, de Boer RA. ST2 and galectin-3: ready for prime time? EJIFCC. 2016; 3: 238-252.
20. Maisel AS, Choudhary R. Biomarkers in acute heart failure - state of the art. Nat Rev Cardiol. 2012; 9: 478-490.
21. Qiu-Sheng Yin, Bing Shi, Lan Dong, Lei Bi. Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure. J Geriatr Cardiol. 2014 Mar; 11 (1): 79-82. doi: 10.3969/j.issn.1671-5411.2014.01.014.
22. Malinova LI, Podbolotov RA, Povarova TV, Pletneva GF. Natriuretic peptides and Galectin-3 in senile heart failure patients with preserved ejection fraction. Saratov Journal of Medical Scientific Research. 2015; 1: 41-46. [In Russ, English abstract].
23. Coromilas E, Que-Xu E, Moore D, Kato TS, Wu Ch, JiR, Givens R et al. Dynamics and prognostic role of galec-tin-3 in patients with advanced heart failure, during left ventricular assist device support and following heart transplantation. BMC Cardiovasc Disord. 2016; 16: 138-148.
24. Beiras-Ferdnandez A, Weis F, Rothkopf J, Kaczmarec I, Ledderose C, Dick A et al. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation. Ann Transplant. 2013; 18: 643-650.
25. Drapkina OM, Emel’yanovAV Fibroz i fibrillyatsiya predserdiy - mek-hanizmy i lechenie. Arterial’naya gipertenziya. 2013; 19: 487-494. [In Russ, English abstract].
26. Lok SI, Nous FM, van Kuik J et al. Myocardial fibrosis and pro-fibrotic markers in end-stage heart failure patients during continuous-flow left ventricular assist device support. Eur J Cardiothorac Surg. 2015; 48: 407-415.
27. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, De Boer RA. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2013; 33 (1): 67-75.
28. Traber PG, Chou H, Zomer E, Hong F, Klyosov A, Fiel MI, Friedman SL. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacet-amide-induced liver disease. PLoSOne. 2013; 8: e75361.
29. Dubolazova YuV Ocenka klinicheskogo techeniya khronicheskoj serdechnoj nedostatochnosti s sokhranennoj frakciej vy'brosa: Avtoref dis. ... kand. med. nauk. M., 2012. [In Russ, English abstract]
30. Lakomkin SV, Skvortsov AA, Goryunova TV, Masenko VP, Tereshchenko SN. Galektin-3 - novyy marker diagnos-tiki i prognoza khronicheskoy serdechnoy nedostatochnosti. Kardiologiya. 2012; 3: 45-52. [In Russ, English abstract].
31. Gandhi PU, Motiwala SR, Belcher AM, Gaggin HK, Weiner RB, Baggish AL, Januzzi JL. Galectin-3 and mi-neralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. American Heart Journal. 2015; 169 (3): 404-411.e3.
32. MaiselA, Kim P Galectin-3 After Heart Transplantation: Does it Get Better? JACC: Heart Failure. 2016; 4 (11): 857-859.
33. Maisel A, Kim P, Stendardi W. Galectin-3 After Heart Transplantation Does it Get Better? JACC: Heart failure. 2016; 4(11).
34. Franekova J, Hoskova l, SecnikP, PazdernikM, Kotrba-ta M, Kubicek Z, Jabor A. The role of timely measurement of galectin-3, NT-proBNP, cystatin C, and hsTnT in predicting prognosis and heart function after heart transplantation. Clin Chem Lab Med. 2015; 2: 339-344.
35. Grupper A, Nativi-Nativi J, Maleszewski JJ, Geske JR, Kremers WK, Edwards BS et al. Circulating galectin-3 levels are persistently elevated after heart transplantation and are associated with renal dysfunction. JACC: Heart Failure. 2016; 4: 847-856.
Review
For citations:
Ulybysheva A.A., Shevchenko O.P., Gichkun O.E., Shevchenko A.О. Galectin-3 in heart recipients. Russian Journal of Transplantology and Artificial Organs. 2019;21(2):145-149. (In Russ.) https://doi.org/10.15825/1995-1191-2019-2-145-149
Views:
921
Email this article 